4//SEC Filing
Caughey Elaine 4
Accession 0000899243-23-006984
CIK 0001815442other
Filed
Mar 2, 7:00 PM ET
Accepted
Mar 3, 4:31 PM ET
Size
12.2 KB
Accession
0000899243-23-006984
Insider Transaction Report
Form 4
Caughey Elaine
Chief Business Officer
Transactions
- Award
Common Stock
2023-03-01+10,557→ 19,700 total - Sale
Common Stock
2023-03-02$30.88/sh−550$16,983→ 19,150 total - Sale
Common Stock
2023-03-02$31.40/sh−164$5,149→ 18,986 total - Award
Stock Option (Right to Buy)
2023-03-01+63,338→ 63,338 totalExercise: $32.07Exp: 2033-02-28→ Common Stock (63,338 underlying)
Footnotes (6)
- [F1]Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in three equal annual installments following March 1, 2023, subject to the reporting person's continued employment through each vesting date.
- [F2]This number includes 465 shares acquired under the Registrant's employee stock purchase plan (the "ESPP") on June 1, 2022 and 1,678 shares acquired under the ESPP on December 1, 2022.
- [F3]Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. These sales were automatic and intended to qualify under Rule 10b5-1.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.30 to $31.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.32 to $31.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F6]The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2023, subject to the reporting person's continued employment through each vesting date.
Documents
Issuer
Kymera Therapeutics, Inc.
CIK 0001815442
Entity typeother
Related Parties
1- filerCIK 0001868668
Filing Metadata
- Form type
- 4
- Filed
- Mar 2, 7:00 PM ET
- Accepted
- Mar 3, 4:31 PM ET
- Size
- 12.2 KB